Cell Medica acquires Delenex Therapeutics
Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, announced today the acquisition of Delenex Therapeutics AG, a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics.
The acquisition will enable Cell Medica to accelerate the development of gene-modified immune cell products with enhanced potency for the treatment of cancer. Delenex’s proprietary PENTRA® technology allows the rapid development of antibody therapeutics within a humanized framework. The Delenex technology and expertise will be integrated with Cell Medica’s product development programme aimed at creating next generation Chimeric Antigen Receptor (CAR)-modified cellular immunotherapies with improved functionality and specificity. Financial details were not disclosed.
Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company). The Delenex scientific team and laboratory facilities based in Schlieren, Switzerland will form a key part of Cell Medica’s international R&D operations and will be re-named Cell Medica Switzerland AG.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.